2025-05-14 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the data you've provided, formatted as requested:

## JNJ (Johnson & Johnson) Analysis

**Company Overview:** Johnson & Johnson (JNJ) is a global healthcare company engaged in the research and development, manufacture, and sale of a broad range of products in the healthcare field.

### 1. Performance vs. S&P 500 (VOO)

*   **JNJ Cumulative Return:** 17.91%
*   **VOO Cumulative Return:** 81.82%
*   **Performance Difference (JNJ - VOO):** -63.9%
*   **Relative Performance Difference:** 13.3 (Indicates JNJ's underperformance is in the lower end of its historical range compared to VOO)

**Analysis:** JNJ has significantly underperformed the S&P 500 over the analyzed period. The relative performance difference suggests that while the underperformance is substantial, it's not unprecedented in JNJ's historical context relative to the S&P 500.

**Alpha, Beta Analysis Table:**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
| ---------- | ------ | ----- | ------ | ----- | ------ |
| 2015-2017  | 28.0%  | 56.0% | -1.0%  | 0.0   | 274.9  |
| 2016-2018  | 10.0%  | 10.8% | -7.0%  | 0.0   | 260.8  |
| 2017-2019  | 20.0%  | 10.8% | -9.0%  | 0.7   | 303.1  |
| 2018-2020  | 14.0%  | 59.8% | -12.0% | 0.5   | 335.9  |
| 2019-2021  | 28.0%  | 59.9% | -26.0% | 0.3   | 374.3  |
| 2020-2022  | 4.0%   | 61.2% | -2.0%  | 0.3   | 396.7  |
| 2021-2023  | -19.0% | 61.2% | -35.0% | 0.4   | 362.6  |
| 2022-2024  | -31.0% | 61.2% | -47.0% | 0.3   | 345.2  |
| 2023-2025  | -8.0%  | 69.6% | -38.0% | 0.1   | 357.2  |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) shows varying performance over different periods, with recent periods showing negative growth.
*   **MDD:** The Maximum Drawdown (MDD) indicates significant potential losses, especially in recent years, highlighting volatility and risk.
*   **Alpha:** The consistently negative Alpha suggests underperformance compared to its benchmark, meaning it's not generating excess returns relative to the risk taken.
*   **Beta:** The low Beta values (close to 0) indicate that JNJ has a low correlation with the overall market (S&P 500) during these periods. It might react less to broad market movements.
*   **Cap(B):** Market capitalization fluctuates over the years, peaking and then declining slightly, reflecting changing investor sentiment and company valuation.

### 2. Recent Price Action

*   **Current Price:** $148.44
*   **Previous Close:** $154.14
*   **Price Change:** -$3.7
*   **5-Day Moving Average:** $153.95
*   **20-Day Moving Average:** $155.10
*   **60-Day Moving Average:** $158.91

**Analysis:** The price has recently declined significantly (change of -$3.7).  The price is below all three moving averages (5, 20, and 60-day), suggesting a short-term downtrend. The significant price drop compared to the previous close indicates negative momentum.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.348 (Low Risk)
*   **RSI:** 32.09 (Approaching oversold territory)
*   **PPO:** -0.207 (Negative, indicating a downtrend)
*   **Recent (20-day) Relative Performance Divergence Change:** -14.4 (Negative, confirming a short-term decline)
*   **Expected Return:** -196.2% (Significantly negative, indicating potential underperformance compared to the S&P 500 for long-term investments)

**Analysis:**

*   The low MRI suggests that the overall market risk is currently low.
*   The RSI value indicates that the stock is nearing oversold conditions, which could potentially signal a future reversal.
*   The negative PPO and 20-day relative performance divergence change both support the downtrend observed in the price action.
*   The substantial negative expected return is a major red flag, suggesting significant potential underperformance compared to the S&P 500 over the long term.  This would warrant further investigation. The large change from previous close (-$3.7) reinforces the current negative trend.

### 4. Recent News & Significant Events

*   **2025-05-10:** Major business developments, regulatory changes, or market events impacting JNJ.
*   **2025-05-11:** Analysts discussing JNJ's performance and outlook.
*   **2025-05-12:** Notable volatility in JNJ's stock price.
*   **2025-05-13:** Market experts highlighting risks and opportunities, advising investors to monitor news and announcements.

**Analysis:**  The news indicates that JNJ is currently experiencing significant events that are causing volatility and warrant close monitoring.  Analysts are actively discussing the company's performance, suggesting a heightened level of scrutiny.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출        |
| ---------- | ---- | ----------- |
| 2025-04-23 | 4.57 | 21.89 B$   |
| 2024-10-23 | 1.12 | 22.47 B$   |
| 2024-07-25 | 1.95 | 22.45 B$   |
| 2024-05-01 | 1.35 | 21.38 B$   |
| 2025-04-23 | 1.35 | 21.38 B$   |

**Analysis:**

*   **EPS:** Earnings per share (EPS) fluctuates, with a high value in the recent period (4.57) but variation across other quarters.
*   **Revenue:** Revenue has generally been stable but shows some fluctuation over the reported quarters.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
| ---------- | --------- | ------------- |
| 2025-03-31 | $21.89B   | 66.40%        |
| 2024-12-31 | $22.52B   | 68.35%        |
| 2024-09-30 | $22.47B   | 69.01%        |
| 2024-06-30 | $22.45B   | 69.40%        |
| 2024-03-31 | $21.38B   | 69.55%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE     |
| ---------- | --------- | ------- |
| 2025-03-31 | $78.11B   | 14.08%  |
| 2024-12-31 | $71.49B   | 4.80%   |
| 2024-09-30 | $70.16B   | 3.84%   |
| 2024-06-30 | $71.54B   | 6.55%   |
| 2024-03-31 | $70.02B   | 4.65%   |

**Analysis:**

*   **Revenue:** Revenue has been relatively stable, but it decreased in the most recent quarter.
*   **Profit Margin:** The profit margin has decreased in the most recent quarter, indicating potential cost pressures or pricing issues.
*   **Equity:** Equity has generally increased over the periods, reflecting the company's retained earnings.
*   **ROE:** The Return on Equity (ROE) saw a significant spike in the recent quarter, which could indicate improved efficiency in utilizing equity.

### 7. Overall Summary

Based on the provided data, Johnson & Johnson (JNJ) presents a mixed picture:

*   **Underperformance:** JNJ has significantly underperformed the S&P 500, and the negative expected return suggests potential continued underperformance. The Alpha and Beta analysis also shows the underperformance.
*   **Downtrend:** Recent price action indicates a downtrend, with the price below key moving averages and negative momentum.
*   **Low Risk:** The low MRI suggests that the overall market risk is low, but the specific risks for JNJ appear elevated.
*   **Volatility:** News indicates recent events have caused volatility in JNJ's stock.
*   **Financial Health:** While revenue and profit margins have shown some fluctuations, the company's equity has generally increased. The latest ROE saw a significant spike, indicating the company may be more efficiently using equity.
*   **Earnings:** EPS varies across quarters, and revenue also shows some fluctuation.

**Conclusion:**

The analysis suggests caution is warranted regarding JNJ. The underperformance relative to the S&P 500, negative expected return, and recent price declines are concerning. The news-driven volatility adds another layer of uncertainty. However, the company's underlying financial health, as indicated by its equity and ROE, is relatively stable, and the approaching oversold territory (based on RSI) could present a potential opportunity for reversal if the company can address its current challenges. Investors should closely monitor the news and any company announcements to get a better understanding of the factors driving the current performance. Further investigation into the reasons behind the negative expected return and decreasing profit margin is highly recommended.
